Fasenra Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Benralizumab

Indications/Uses

Add-on maintenance treatment in adults w/ severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists; relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Click to view Fasenra detailed prescribing information

Dosage/Direction for Use

SC Inj into thighs, abdomen or upper arm. Asthma 30 mg every 4 wk for 1st 3 doses, then every 8 wk thereafter. EGPA 30 mg every 4 wk.

Click to view Fasenra detailed prescribing information

Overdosage

View Fasenra overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Fasenra detailed prescribing information

Special Precautions

Acute systemic reactions including anaphylactic & hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, papular urticaria, rash). Discontinue treatment permanently in the event of hypersensitivity reaction; if patient becomes infected w/ helminth while receiving therapy & does not respond to anti-helminth treatment. Not to be used to treat acute asthma exacerbations. Not to be inj into areas where skin is tender, bruised, erythematous or hardened. Avoid abrupt discontinuation. Patients w/ active organ threatening or life-threatening manifestations of EGPA. History of anaphylaxis unrelated to benralizumab. Monitor patients for appropriate time after administration of treatment. Treat patients w/ pre-existing helminth infections before initiating therapy. Avoid use during pregnancy. Lactation. Childn (<6 yr) & adolescents 6-17 yr w/ asthma; <18 yr w/ EGPA.

Click to view Fasenra detailed prescribing information

Use In Pregnancy & Lactation

Click to view Fasenra detailed prescribing information

Adverse Reactions

Pharyngitis; hypersensitivity reactions; headache; pyrexia, inj site reaction.

Click to view Fasenra detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Fasenra detailed prescribing information

Storage

View Fasenra storage conditions for details to ensure optimal shelf-life.

Description

View Fasenra description for details of the chemical structure and excipients (inactive components).

Action

View Fasenra mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.

Thai FDA Category

Patient Counseling Information

View Fasenra patient counselling information

Presentation/Packing

Form

Fasenra soln for inj 30 mg/mL

Packing/Price

1's

Fasenra

Manufacturer:

AstraZeneca AB

Distributor:

Zuellig Pharma

Marketer:

AstraZeneca